BIOXYTRAN, INC 8-K

What Happened
Bioxytran, Inc. (NASDAQ: BIXT) announced on February 11, 2026 via an 8‑K (Item 8.01) that it reported positive Phase 2 clinical results for its candidate ProLectin‑M, highlighting rapid viral clearance. The company attached a press release describing the results as an exhibit to the filing.

Key Details

• Filing date: February 11, 2026 (Form 8‑K, Item 8.01).
• Program: ProLectin‑M — reported Phase 2 clinical results described as "positive" and demonstrating "rapid viral clearance."
• Disclosure: Press release titled “Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin‑M” filed as Exhibit 99.1 to the 8‑K.
• Ticker: Bioxytran trades under BIXT.

Why It Matters
Positive Phase 2 data is a material clinical milestone that advances Bioxytran’s development pipeline and may influence investor interest and the company’s regulatory and development plans. Retail investors should read the attached press release for the detailed data and monitor upcoming company disclosures for full study results, next steps, and any regulatory or commercial guidance.